Stockholm September 14th, 2021
BioLamina AB expands production and office space to meet the fast-growing customer demand
BioLamina (Stockholm) is under rapid growth. The company is expanding its production facility to increase its production capacity. BioLamina is also adding to its current office space to accommodate a steadily growing team. This ongoing expansion is transpiring as an extension of the current premises of the company in Stockholm, Sweden.
Biolaminin® have become the preferred cell culture substrates for the primary cell culture market. The volumes purchased world-wide are increasing significantly each year and have seen an exponential rise in 2021. To meet this increasing global demand, BioLamina is now temporarily establishing more production capacity for its best-selling product, human recombinant laminin 521 substrate at Testa Center in Uppsala, Sweden.
As part of the long-term solution and expansion of the production facility in Stockholm, BioLamina has engaged QleanAir to develop and build a 340 m² large cleanroom facility for production and research within process development, matrix biology and cellular assays. The new premises will also allow the company to increase the storage capacity and improve logistical operations. The new facility comes in addition to the current manufacturing facility and will result in a fourfold increase of the company’s overall production capacity. This new facility is expected to begin operations during the first quarter of 2022. An additional area of 500 m2 of office space will also be added enabling the company to further expand its operations in Sweden.
“It is amazing that BioLamina is growing at such a fast rate. These are very exciting times for the company. However, we are not oblivious to the challenges that come along with it. Therefore, we are undertaking all possible measures to foresee them and minimize any negative impact” said Anders Lindblad, Interim CEO and COO at BioLamina. He added: “We recognize that this rapid growth is attributed to the trust our customers have placed in our company. Hence addressing our customers’ needs is vital to us. Keeping them in perspective, not only are we expanding our production facility and running our current production at full capacity, but we are also temporarily increasing our production capacity at Testa Center. Moreover, we can now better accommodate our growing team, that brings the necessary skills required to support the scale-up phase of BioLamina.”
For more information, please contact:
Anders Lindblad, Interim CEO and COO
Phone: +46 70 339 18 87
Press images: www.biolamina.com/press-room-images
About BioLamina AB
The innovative products of BioLamina solve many of the technical problems associated with maintaining human pluripotent stem cells in a naive state and to pushing these stem cells towards different specialized cell types, such as neurons, heart cells, and liver cells. Our flagship products, our biorelevant human recombinant laminin isoforms, Biolaminin, are defined cell culture matrices that successfully imitate the natural, cell-specific cell-matrix interaction in the cell culture dish, allowing the cells to thrive and maintain their function. Our products are a powerful resource for scientists working both within basic research as well as in regenerative medicine companies with focus on cell therapy applications.
For more information: www.biolamina.com